KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RMD) Gross Profit (2016 - 2025)

Historic Gross Profit for Resmed (RMD) over the last 17 years, with Q4 2025 value amounting to $878.7 million.

  • Resmed's Gross Profit rose 1696.44% to $878.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.3 billion, marking a year-over-year increase of 1422.48%. This contributed to the annual value of $3.1 billion for FY2025, which is 1505.17% up from last year.
  • Per Resmed's latest filing, its Gross Profit stood at $878.7 million for Q4 2025, which was up 1696.44% from $820.8 million recorded in Q3 2025.
  • Over the past 5 years, Resmed's Gross Profit peaked at $878.7 million during Q4 2025, and registered a low of $447.3 million during Q1 2021.
  • Over the past 5 years, Resmed's median Gross Profit value was $617.6 million (recorded in 2023), while the average stood at $636.4 million.
  • As far as peak fluctuations go, Resmed's Gross Profit crashed by 53.46% in 2021, and later skyrocketed by 2576.46% in 2023.
  • Over the past 5 years, Resmed's Gross Profit (Quarter) stood at $504.3 million in 2021, then grew by 14.95% to $579.7 million in 2022, then rose by 11.6% to $646.9 million in 2023, then rose by 16.13% to $751.3 million in 2024, then rose by 16.96% to $878.7 million in 2025.
  • Its last three reported values are $878.7 million in Q4 2025, $820.8 million for Q3 2025, and $820.1 million during Q2 2025.